Clinical trial · Interventional
Standard Treatments of Very-early Stage Hepatocellular Carcinoma
The Research on Standard Treatments of Very-early Stage Hepatocellular Carcinoma: a Randomized Clinical Trial
NCT02728193CI-TRIAL-00021639completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of our study was to elucidate the difference in the rates of complication, hospitalization days, medical expenses, MRI showed that the degree of tumor necrosis, and overall survival rates of the therapies between PEI, MVA and RFA, and make the standard for minimally invasive treatment of very early stage HCC.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Very-early Stage | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MWV | Procedure | — | UNRESOLVED |
| PEI | Procedure | — | UNRESOLVED |
| RFA | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- RFA
- description
- Radiofrequency ablation
- interventionNames
- Procedure: RFA
- type
- EXPERIMENTAL
- label
- MWV
- description
- Microwave ablation
- interventionNames
- Procedure: MWV
- type
- EXPERIMENTAL
- label
- PEI
- description
- Percutaneous ethanol injection
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Preoperative clinical, imaging and tumor markers were diagnosed as hepatocellular carcinoma 2. Tumor diameter\<2cm 3. Child-Pugh class A liver function 4. Without major organ dysfunction 5. male or female patients \> 18 years and \<=70 years of age 6. Voluntary participation in this clinical trial Exclusion Criteria: 1. Other anticancer treatment before therapy 2. Patients with apparent major organs (i.e. cardiac, pulmonary, cerebral and renal) dysfunction, which may affect the treatment of liver cancer 3. Patients with other diseases that may affect the treatment of this treatment 4. History of other malignant tumors 5. Patients who are participating in other clinical trials 6. Pregnant, lactating women
References
Publications (0)
Data not yet available
No reference posted for this study.